Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Global Intelligent Asthma Monitoring Devices Market is valued at approximately USD 282.48 million in 2022 and is anticipated to grow with a healthy growth rate of more than 25.1% over the forecast ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Cole Schmidtknecht expected to pay $66.86 for a three-month supply of his preventative asthma inhalers in January 2024 when ...

In early childhood, Schmidtknecht’s asthma meant being tethered to an albuterol emergency inhaler and unexpected ... possible” that its manufacturer, GlaxoSmithKline, stopped offering Optum ...

After some disappointing earlier results for GSK’s new asthma treatment Revlar Ellipta ... The drug, which combines an inhaled corticosteroid (ICS) with a long-acting beta 2 agonist, was ...

According to a press release, more than 1 million Arizonans depended on this long-term asthma control inhaler. Prior to ending production, GSK had hiked up Flovent’s price “far beyond ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare form of vasculitis that causes inflammation or swelling in the small and ...

accusing it of gaming the system by simply renaming an asthma drug to increase its profits. The lawsuit filed in Maricopa County Superior Court says GlaxoSmithKline stopped producing its Flovent ...